Globus Medical price target lowered to $82 from $90 at Truist

Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares. The firm is adjusting its 2025 quarterly revenue forecasts to reflect management commentary at a recent competitor conference around revenue cadence, the analyst tells investors in a research note. Truist adds that its reduced price target is also reflecting the recent multiple compression for the market and the peer group over the last few week.